-
Something wrong with this record ?
Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research
SR. Welch, JP. Bilello, K. Carter, L. Delang, L. Dirr, D. Durantel, JY. Feng, BB. Gowen, LJ. Herrero, Z. Janeba, G. Kleymann, AA. Lee, C. Meier, J. Moffat, LM. Schang, JT. Schiffer, KL. Seley-Radtke, TP. Sheahan, JR. Spengler
Language English Country Netherlands
Document type Congress
- MeSH
- Antiviral Agents * therapeutic use pharmacology MeSH
- COVID-19 MeSH
- COVID-19 Drug Treatment MeSH
- Humans MeSH
- Drug Discovery MeSH
- Drug Development MeSH
- Vaccine Development MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Congress MeSH
- Geographicals
- Australia MeSH
The 37th International Conference on Antiviral Research (ICAR) was held in Gold Coast, Australia, May 20-24, 2024. ICAR 2024 featured over 75 presentations along with two poster sessions and special events, including those specifically tailored for trainees and early-career scientists. The meeting served as a platform for the exchange of cutting-edge research, with presentations and discussions covering novel antiviral compounds, vaccine development, clinical trials, and therapeutic advancements. A comprehensive array of topics in antiviral science was covered, from the latest breakthroughs in antiviral drug development to innovative strategies for combating emerging viral threats. The keynote presentations provided fascinating insight into two diverse areas fundamental to medical countermeasure development and use, including virus emergence at the human-animal interface and practical considerations for bringing antivirals to the clinic. Additional sessions addressed a variety of timely post-pandemic topics, such as the hunt for broad spectrum antivirals, combination therapy, pandemic preparedness, application of in silico tools and AI in drug discovery, the virosphere, and more. Here, we summarize all the presentations and special sessions of ICAR 2024 and introduce the 38th ICAR, which will be held in Las Vegas, USA, March 17-21, 2025.
Baker Institute and Department of Microbiology and Immunology Cornell University Ithaca NY USA
Department of Chemistry and Biochemistry University of Maryland Baltimore County Baltimore MD USA
Department of Epidemiology University of North Carolina at Chapel Hill Chapel Hill NC USA
Department of Microbiology and Immunology SUNY Upstate Medical University Syracuse NY USA
Division of Allergy and Infectious Diseases University of Washington Seattle WA USA
Fred Hutchinson Cancer Research Center Vaccine and Infectious Diseases Division Seattle WA USA
Gilead Sciences Inc Foster City CA USA
Innovative Molecules GmbH Lipowsky Str 10 81373 Munich Bavaria Germany
Institute for Biomedicine and Glycomics Griffith University Southport QLD Australia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003159
- 003
- CZ-PrNML
- 005
- 20250206104056.0
- 007
- ta
- 008
- 250121e20241113ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.antiviral.2024.106037 $2 doi
- 035 __
- $a (PubMed)39542140
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Welch, Stephen R $u Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: swelch1@cdc.gov
- 245 10
- $a Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research / $c SR. Welch, JP. Bilello, K. Carter, L. Delang, L. Dirr, D. Durantel, JY. Feng, BB. Gowen, LJ. Herrero, Z. Janeba, G. Kleymann, AA. Lee, C. Meier, J. Moffat, LM. Schang, JT. Schiffer, KL. Seley-Radtke, TP. Sheahan, JR. Spengler
- 520 9_
- $a The 37th International Conference on Antiviral Research (ICAR) was held in Gold Coast, Australia, May 20-24, 2024. ICAR 2024 featured over 75 presentations along with two poster sessions and special events, including those specifically tailored for trainees and early-career scientists. The meeting served as a platform for the exchange of cutting-edge research, with presentations and discussions covering novel antiviral compounds, vaccine development, clinical trials, and therapeutic advancements. A comprehensive array of topics in antiviral science was covered, from the latest breakthroughs in antiviral drug development to innovative strategies for combating emerging viral threats. The keynote presentations provided fascinating insight into two diverse areas fundamental to medical countermeasure development and use, including virus emergence at the human-animal interface and practical considerations for bringing antivirals to the clinic. Additional sessions addressed a variety of timely post-pandemic topics, such as the hunt for broad spectrum antivirals, combination therapy, pandemic preparedness, application of in silico tools and AI in drug discovery, the virosphere, and more. Here, we summarize all the presentations and special sessions of ICAR 2024 and introduce the 38th ICAR, which will be held in Las Vegas, USA, March 17-21, 2025.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a antivirové látky $x terapeutické užití $x farmakologie $7 D000998
- 650 _2
- $a COVID-19 $7 D000086382
- 650 _2
- $a farmakoterapie COVID-19 $7 D000093485
- 650 _2
- $a vyvíjení léků $7 D000076722
- 650 _2
- $a objevování léků $7 D055808
- 650 _2
- $a vývoj vakcíny $7 D000087506
- 651 _2
- $a Austrálie $7 D001315
- 655 _2
- $a kongresy $7 D016423
- 700 1_
- $a Bilello, John P $u Gilead Sciences, Inc., Foster City, CA, USA
- 700 1_
- $a Carter, Kara $u Evotec US, Princeton, NJ, USA
- 700 1_
- $a Delang, Leen $u Virus-Host Interactions & Therapeutic Approaches Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
- 700 1_
- $a Dirr, Larissa $u Institute for Biomedicine and Glycomics, Griffith University, Southport, QLD, Australia
- 700 1_
- $a Durantel, David $u Centre International de Recherche en Infectiologie (CIRI), Inserm_U1111, CNRS_UMR5308, Université Claude Bernard Lyon 1, F-69007, Lyon, France
- 700 1_
- $a Feng, Joy Y $u Division of the Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA
- 700 1_
- $a Gowen, Brian B $u Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, UT, USA
- 700 1_
- $a Herrero, Lara J $u Institute for Biomedicine and Glycomics, Griffith University, Southport, QLD, Australia
- 700 1_
- $a Janeba, Zlatko $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 160 00, Prague, Czech Republic
- 700 1_
- $a Kleymann, Gerald $u Innovative Molecules GmbH, Lipowsky Str. 10, 81373, Munich, Bavaria, Germany
- 700 1_
- $a Lee, Alpha A $u PostEra Inc, 1 Broadway, Cambridge, MA, USA
- 700 1_
- $a Meier, Chris $u Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Martin-Luther-King-Platz 6, Hamburg, Germany
- 700 1_
- $a Moffat, Jennifer $u Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA
- 700 1_
- $a Schang, Luis M $u Baker Institute and Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA
- 700 1_
- $a Schiffer, Joshua T $u Fred Hutchinson Cancer Research Center, Vaccine and Infectious Diseases Division, Seattle, WA, USA; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA
- 700 1_
- $a Seley-Radtke, Katherine L $u Department of Chemistry & Biochemistry, University of Maryland, Baltimore County, Baltimore, MD, USA
- 700 1_
- $a Sheahan, Timothy P $u Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 700 1_
- $a Spengler, Jessica R $u Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: jspengler@cdc.gov
- 773 0_
- $w MED00000480 $t Antiviral research $x 1872-9096 $g Roč. 232 (20241113), s. 106037
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39542140 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104052 $b ABA008
- 999 __
- $a ok $b bmc $g 2263109 $s 1239166
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 232 $c - $d 106037 $e 20241113 $i 1872-9096 $m Antiviral research $n Antiviral Res $x MED00000480
- LZP __
- $a Pubmed-20250121
